Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXPBiotechnology
-$0.24 today
- Market cap
- $54.80M
- Beta
- 1.68
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$10.75
Volume 1.04M
Average 0.49M
TNXP Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin widens to -584.4%
Net margin was -584.4% in Q1 FY2026, up 108.5 pp from a year earlier. On a trailing-twelve-month basis it was -839.5%, up 474.4 pp year over year.
Context
- Net margin widened in 2 of the last 2 fiscal years.
- FY2025 was the highest level in the 3 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 2 analysts of -157.2% for the fiscal year ending Dec 2026, up from -946.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -584.4%+285.9 pp QoQ
- Last fiscal yearDec 2025
- -946.2%+342.0 pp YoY
- LTMMar 2026
- -839.5%+474.4 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +108.5 pp | +784.0 pp | +675.6 pp |
| 1 year | +342.0 pp | +789.0 pp | +447.0 pp |
| 3 years | — | +929.9 pp | — |
| 5 years | +945.8 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -946.2%
- Year-over-year change
- +342.0pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -946.2% | +342.0pp |
| FY2024 | 2024-12-31 | -1288.3% | +213.5pp |
| FY2023 | 2023-12-31 | -1501.8% | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
Net Margin vs competitors
How TNXP compares with its peers on the latest reported figures
- TNXP's LTM Mar 2026 net margin of -839.5% is the highest of the 6 companies compared; the peer median is -3832.0%.
- Its year-over-year change of +474.4 pp is the highest of 4, against a peer median of -1372.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -839.5% | +474.4 pp | — | |
| FY2025 | -1764.5% | -1372.5 pp | -1663.8 pp | |
| LTM Mar 2026 | -2056.8% | -737.9 pp | -1758.5 pp | |
| LTM Mar 2026 | -3832.0% | — | -2911.0 pp | |
| LTM Mar 2026 | -4088.8% | — | — | |
| LTM Mar 2026 | -143627.1% | -160183.1 pp | -132411.6 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
ELTXElicio Therapeutics, Inc. | FY2025 | — | — | — |
| Peer median (excluding TNXP) | -3832.0% | -1372.5 pp | -2334.8 pp | |
Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 7.77M | 10.09M | 13.11M |
| Cost of Revenue | 0 | 0 | 4.74M | 7.77M | 8.57M |
| Gross Profit | 0 | 0 | 3.03M | 2.33M | 4.54M |
| Gross Margin | — | — | 39.0% | 23.1% | 34.7% |
| Research & Development | 68.84M | 81.88M | 86.66M | 40.45M | 44.49M |
| Selling, General & Admin | 23.47M | 30.22M | 34.75M | 40.1M | 85.76M |
| Operating Expenses | 92.31M | 112.09M | 121.41M | 139.03M | 130.25M |
| Depreciation & Amortization | 50K | 1.25M | 4.29M | 3.42M | 1.93M |
| EBITDA | (92.24M) | (108.97M) | (112.37M) | (74.32M) | (122.01M) |
| EBITDA Margin | — | — | -1446.5% | -736.3% | -930.9% |
| Operating Income | (92.31M) | (112.09M) | (118.38M) | (136.7M) | (125.7M) |
| Operating Margin | — | — | -1523.9% | -1354.3% | -959.1% |
| Interest Income | 25K | 1.87M | 0 | 0 | 4.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 89K |
| Other Income / Expenses | 25K | 1.87M | 1.72M | 6.67M | 1.68M |
| Income Before Tax | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Pre-Tax Margin | — | — | -1501.8% | -1288.3% | -946.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Net Margin | — | — | -1501.8% | -1288.3% | -946.2% |
| EPS (Basic) | (163,968.00) | (811.68) | (6,368.84) | (176.60) | (14.57) |
| EPS (Diluted) | (163,968.00) | (811.68) | (6,368.84) | (176.60) | (14.57) |
| Weighted Avg Shares | 563 | 3.07M | 1.83M | 2.26M | 8.51M |
| Weighted Avg Shares (Diluted) | 563 | 3.07M | 1.83M | 2.26M | 8.51M |
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.